• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Evaluating the efficacy of 8Spheres microsphere combined with Iodine-125 seeds in the treatment of advanced lung squamous cell carcinoma presenting with hemoptysis: A retrospective study.

作者信息

Ran Linhao, Liang Huan, Chen Jiangwei, Fu Weichen, Yang Dichun, Li Fan, Jiang Li, Liu Ying

机构信息

Department of Nuclear Medicine, Banan Hospital of Chongqing Medical University, Chongqing 401320, PR China.

Department of Ultrasound, Banan Hospital of Chongqing Medical University, Chongqing 401320, PR China.

出版信息

Eur J Radiol. 2025 Oct;191:112295. doi: 10.1016/j.ejrad.2025.112295. Epub 2025 Jul 8.

DOI:10.1016/j.ejrad.2025.112295
PMID:40645027
Abstract

BACKGROUND

Hemoptysis is a critical complication in advanced lung squamous cell carcinoma (LUSC). This study aims to evaluate the effectiveness and safety of 8Spheres microspheres embolization combined with iodine-125 seed implantation for managing hemoptysis in patients with advanced LUSC.

METHODS

A retrospective analysis was performed involving 45 patients diagnosed with advanced squamous cell carcinoma and experiencing hemoptysis. The primary endpoints included the control rate of hemoptysis within 24 h post-embolization, hemoptysis-free survival (HFS), and overall survival (OS). Secondary endpoints comprised progression-free survival (PFS) and the occurrence of complications.

RESULTS

The technical success rate was 100 %. Within 24 h following the 8Spheres microspheres embolization, hemoptysis was completely resolved in 31 patients, while the remaining patients showed a reduction of over 70 % in hemoptysis volume. The median HFS, median OS, and median PFS of all patients were 16 months, 15 months, and 10 months, respectively. Patients who continued with immunotherapy after the procedure demonstrated significant improvements in median HFS, median OS, and median PFS (median HFS: not reached vs. 10 months, P = 0.008; median OS: 16 months vs. 11 months, P < 0.001; median PFS: 12 months vs. 7 months, P = 0.003). The use of preoperative bronchial artery CTA imaging was shown to significantly decrease operative time (42.69 ± 8.49 vs. 64.81 ± 7.55, P < 0.05). Postoperative adverse reactions were mild and subsided with symptomatic treatment.

CONCLUSION

The combination of 8Spheres microspheres embolization and iodine-125 seed implantation is an effective and safe approach for managing hemoptysis in advanced lung squamous cell carcinoma, representing a promising therapeutic option for affected patients. Furthermore, preoperative CTA examination can significantly shorten operative time, while ongoing immunotherapy may help delay tumor progression.

摘要

相似文献

1
Evaluating the efficacy of 8Spheres microsphere combined with Iodine-125 seeds in the treatment of advanced lung squamous cell carcinoma presenting with hemoptysis: A retrospective study.
Eur J Radiol. 2025 Oct;191:112295. doi: 10.1016/j.ejrad.2025.112295. Epub 2025 Jul 8.
2
Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: a multicenter, real-world, retrospective cohort study from China (NCT06478355).一线化疗免疫治疗联合或不联合放疗对局部晚期或转移性食管鳞状细胞癌患者预后的影响:一项来自中国的多中心、真实世界、回顾性队列研究(NCT06478355)
Front Immunol. 2025 Jul 28;16:1633930. doi: 10.3389/fimmu.2025.1633930. eCollection 2025.
3
Bronchial artery embolization for hemoptysis in adult patients with cystic fibrosis: a single-center retrospective study.成人囊性纤维化患者咯血的支气管动脉栓塞治疗:单中心回顾性研究。
Acta Radiol. 2023 Apr;64(4):1381-1389. doi: 10.1177/02841851221126833. Epub 2022 Sep 14.
4
The combined treatment of CT-guided percutaneous 125I seed implantation and chemotherapy for non-small-cell lung cancer.CT 引导下经皮 125I 种子植入联合化疗治疗非小细胞肺癌。
J Cancer Res Clin Oncol. 2011 Dec;137(12):1813-22. doi: 10.1007/s00432-011-1048-3. Epub 2011 Sep 16.
5
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.比较 PD-1/PD-L1 联合疗法在晚期 NSCLC 一线治疗中的疗效和安全性:一项更新的系统评价和网络荟萃分析。
Clin Transl Oncol. 2024 Oct;26(10):2488-2502. doi: 10.1007/s12094-024-03442-3. Epub 2024 Apr 16.
6
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial.舒格利单抗联合铂类化疗作为转移性非小细胞肺癌一线治疗对比安慰剂(GEMSTONE-302):一项双盲、随机、3期试验的4年结果
Lancet Oncol. 2025 Jul;26(7):887-897. doi: 10.1016/S1470-2045(25)00198-6. Epub 2025 Jun 13.
7
Diagnosis and Embolization of Hemoptysis Associated with the Inferior Phrenic Artery: A Single-Center Study.与膈下动脉相关咯血的诊断与栓塞:一项单中心研究
Acad Radiol. 2025 Sep;32(9):5317-5326. doi: 10.1016/j.acra.2025.05.042. Epub 2025 Jun 2.
8
Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.一线化疗治疗成人局部晚期或转移性非小细胞肺癌的临床效果和成本效益:系统评价和经济评估。
Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310.
9
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益:一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
10
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.未治疗的霍奇金淋巴瘤患者化疗和放疗在第二原发性恶性肿瘤、总生存期和无进展生存期方面的优化:个体参与者数据分析
Cochrane Database Syst Rev. 2017 Sep 13;9(9):CD008814. doi: 10.1002/14651858.CD008814.pub2.